Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension
Marc Humbert
Abstract
<h3>Tweetable abstract</h3> <b>The US Food and Drug Administration has agreed to review an application seeking approval of the activin signalling inhibitor sotatercept as a treatment for adults with pulmonary arterial hypertension</b>https://bit.ly/46zBDPS
Topics & Concepts
Food and drug administrationPulmonary hypertensionSignallingActivin receptorMedicinePulmonary arterial pressureInternal medicinePharmacologyCardiologyReceptorBiologyCell biologyPulmonary Hypertension Research and Treatments